TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07917468: Sintilimab Combined With Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy vs. Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy for Total Neoadju

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07917468 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07917468 Rescue Dossier →